abstract: Recently, it has been shown that ectopic expression of several germ line genes, such as piwi, vasa, nos and aub, drives the growth of malignant brain tumors in Drosophila. A genome-wide association study (GWAS) of 18 000 subjects indicated that genetic variation at 22q12.2, the location of the conserved meiotic gene HORMAD2, may contribute to the risk of lung cancer in Han Chinese individuals. The expression pattern of human HORMAD2 in multiple human tissues was determined by RT-PCR. HORMAD2 protein expression and localization were analyzed in the human testis using immunohistochemistry. The expression of HORMAD2 in lung cancer and normal tissues was studied using quantitative RT-PCR and immunohistochemistry. HORMAD2 is predominantly expressed in human testis and weakly expressed in liver. HORMAD2 is ectopically expressed in nearly 10% of lung cancer samples from Chinese Han individuals. In conclusion, HORMAD2 is a novel cancer/testis gene discovered by GWAS, which may provide a new target for lung cancer research.
Introduction
Human gametogenesis and tumorigenesis share a number of important characteristics (Simpson et al., 2005) . One hundred years ago, cancer was thought to arise from germ cells which failed to complete embryonic migration to the gonads (Gurchot, 1975) . In the testis, the similar features of germ cells and cancer cells include immortalization, which is involved in transformation; ploidy change in germ cell meiosis that may be associated with aneuploidy in cancer cells; and migration which contributes to metastasis (Simpson et al., 2005) . Recently, it has been shown that ectopic expression of several germ line genes, such as piwi, vasa, nos and aub, drives the growth of malignant brain tumors in Drosophila (Janic et al., 2010) .
In normal tissues, cancer/testis (CT) genes are predominantly expressed in germ line cells; however, CT genes are also ectopically activated in a wide range of cancers. The first CT antigen MZ2-E was discovered in the 1990s, and was the first CD8+ T-cell target to be identified in human cancer (van der Bruggen et al., 1991; Van Pel et al., 1995; Chomez et al., 2001 ). To date, over 100 CT genes have been identified by either immunological screening methods or expression database analysis (Scanlan et al., 2004; Chen et al., 2005a; Hofmann et al., 2008) . Many CT genes encode antigens which are immunogenic in cancer patients, and some have potential for use as biomarkers and immunotherapy targets (Hofmann et al., 2008) .
Melanoma, lung cancer and liver cancer have been identified to express high levels of CT genes (Scanlan et al., 2004; Hofmann et al., 2008) . Genome-wide association studies (GWAS) have indicated that genetic variations, including single nucleotide polymorphisms (SNPs) can alter the expression levels of genes Folkersen et al., 2010; Bown et al., 2011) . rs17728461 [Pcombined ¼ 1.1 × 10
211
, odds ratio (OR) ¼ 1.20] and rs36600 (Pcombined ¼ 6.2 × 10
213
, OR ¼ 1.29) are associated with lung cancer GWAS scan of 2331 lung cancer cases and 3077 controls, and also consistently replicated with significant associations in the second stage validation samples among 4030 cases and 4166 controls (Hu et al., 2011b) . A conserved meiotic chromosomal protein coding gene, HORMA domain containing 2 (HORMAD2) (Wojtasz et al., 2009) , is located in this region (see Supplementary data, Fig. S1 ). Investigation of the function and role of HORMAD2 may help to provide novel clinical treatment options for infertility and cancer.
Materials and Methods

Tumor tissue specimens
Lung cancer specimens and the adjacent normal lung tissues were obtained from the Cancer Center of Nanjing Medical University. Each case was histopathologically or cytologically confirmed as lung cancer by at least two pathologists. This study was approved by the Institutional Review Boards of Nanjing Medical University and informed consent was obtained from each subject at recruitment.
RNA extraction, RT-PCR and qualitative RT-PCR
Total RNA was extracted from the lung cancer specimens and adjacent normal lung tissues using the RNeasy Plus Micro Kit with on-column DNase digestion (Qiagen Ltd., Crawley, West Sussex, UK). Randomprimed cDNA was prepared using the PrimeScript TM RT Master Mix (TaKaRa Bio Inc., Otsu, Japan). The cDNA was PCR-amplified using specific primers in 20 ml GoTaq Green Master Mix. The amplification conditions consisted of an initial denaturation at 948C for 5 min, followed by 40 cycles at 948C for 30 s, 558C for 30 s and 728C for 30 s with a final extension at 728C for 10 min human b-actin was amplified as the positive control. The PCR products were analyzed by 1.5% w/v agarose electrophoresis. Qualitative RT-PCR was performed using the ABI PRISM 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA) at 958C for 30 s; with 40 cycles at 958C for 5 s and 558C for 31 s; followed by a typical dissociation stage. b-Actin and HORMAD2 were amplified in parallel as a loading control using specific primers (b-actin forward 5 ′ -GAAATCGTGCGTGACATTAA-3 ′ and b-actin reverse 5
Immunohistochemical analysis
Lung cancer tissue microarrays (US Biomax, Inc., Xi'an, China), containing tumors of known stage and grade, were analyzed by immunohistochemistry as previously described (Zhu et al., 2010) . In brief, after quenching endogenous peroxidase activity, the sections were blocked, incubated overnight at 48C with a specific HORMAD2 antibody (Abcam, Cambridge, UK) and incubated with horse-radish peroxidase-conjugated secondary antibody (Beijing ZhongShan Biotechnology, China). Immunoreactivity was developed using diaminobenzidine (brown staining) and the slides were mounted for bright-field microscopy (Axioskop A1; Zeiss, Germany). To confirm the specificity of the antibody, negative controls were processed in an identical manner, except that the primary antibody was replaced with normal immunoglobulin G (Abcam).
Statistical analysis
Pearson's x 2 tests are performed to detect significant differences in the categorical data using Stata software, version 11.0 (Stata Corp., College Station, TX, USA).
Results
Search for candidate CT genes associated with lung cancer
Genetic variation at six SNPs: rs4488809 at 3q28, rs465498 and rs2736100 at 5p15.33, rs753955 at 13q12.12 and rs17728461 and rs36600 at 22q12.2 were reported in a previous GWAS of lung cancer. The 200 kb regions surrounding these SNPs are associated with an increased risk of cancer (Hu et al., 2011b) . Therefore, we hypothesized that the 200 kb regions surrounding these SNPs may contain genes which are potentially associated with lung cancer according to the published paper (Folkersen et al., 2010) . UniGene indicated that the expression of 354 protein coding genes are restricted to human testis (http://www.ncbi.nlm.nih.gov/UniGene/). The chromosomal locations of the six SNPs and 354 testis-restricted genes were collected from the Ensembl Gene 63 database (http:// www.ensembl.org/biomart/). Two SNPs, rs17728461 and rs36600 at 22q12.2, were found to be located within 200 kb of HORMAD2.
HORMAD2 is expressed in the nuclei of human spermatocytes
Expression of human HORMAD2 was analyzed, using an expressed sequence tag (EST) database from NCBI (http://www.ncbi.nlm.nih. gov/UniGene/). Positive expression was identified in only four tissues: the testis and liver, with low levels in the prostate and brain. Further RT-PCR analysis of multiple-tissue cDNA panels (Clontech Laboratories, Palo Alto, CA, USA) using HORMAD2 specific primers demonstrated that HORMAD2 was expressed in the testis and liver, but not in any of the other somatic tissues tested (Fig. 1) . The expression data of HORMAD2 in the prostate and brain in UniGene differ from our data. This might be caused by false-positive of highthroughput EST data. Both data sets show that HORMAD2 is highly and consistently expressed in the testis. Immunohistochemical staining for HORMAD2 was performed on human testis tissue sections. HORMAD2 protein expression was localized in the nucleus of human spermatocytes (Fig. 2) , similar to the expression pattern of the mouse HORMAD2 homolog (Wojtasz et al., 2009) . Figure 1 Expression profile of HORMAD2 mRNA in 16 normal human tissues. 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas; 9, spleen; 10, thymus; 11, prostate; 12, testis; 13, ovary; 14, small intestine; 15, colon; 16, leukocytes; 17, negative control.
HORMAD2 is ectopically expressed in lung cancer tissues from Chinese Han patients
Quantitative RT -PCR was performed to evaluate the expression of HORMAD2 in lung cancer tissues. Analysis of 20 paired lung cancer specimens and the adjacent normal lung tissues revealed that HORMAD2 was ectopically expressed at high levels in the lung cancer tissue of one patient (Fig. 3A) . Six of these samples are further studied by immunohistochemistry (Fig. 3B) . A strong positive HORMAD2, a novel CT gene signal is detected in the No. 15 cancer tissue, as well as a small amount of HORMAD2 mRNA in Nos. 3, 6, 7, 8 and 16 cancer samples by RT -PCR, although the protein of HORMAD2 were rarely expressed in these samples.
To further investigate the role of HORMAD2 in lung cancer, we conducted an immunohistochemical study using a HORMAD2 specific antibody and a tissue microarray consisting of 90 adenocarcinoma samples and 75 squamous cell carcinoma samples. Nuclear expression of HORMAD2 was observed in nine cases of adenocarcinoma (Fig. 4) and six cases of squamous carcinoma (Fig. 5) .
In lung adenocarcinoma, only TNM stage I tumors expressed nuclear HORMAD2 (Table I ). The pattern of HORMAD2 expression in different pathologic tumor grades was significantly different (one sample had no tumor grade classification). Significantly more grade 2 tumors (8/38; 21.05%) than grade 3 tumors [1/46, 2.17% expressed HORMAD2 (Pearson's chi-square test, P , 0.01; Table I) ]. There was no relationship between the expression of HORMAD2 and the TNM classification (TNM Classification of Malignant Tumors, T describes the size of the tumor and whether it has invaded nearby tissue, N describes regional lymph nodes that are involved and M describes distant metastasis) or pathological grade in squamous cell carcinoma.
Discussion
The discovery of CT genes often depends on the limited number of tumor cell lines and tumor specimens (Chen et al., 2005a; Hofmann et al., 2008) . However, regions of aberration in tumor genomes can also provide clues for the discovery of CT genes, such as RGS22, which was identified from a GWAS study of 18 000 subjects (Hu et al., 2011a) .
The mammalian HORMADs, HORMAD1 and HORMAD2, share homology with the meiosis-specific HORMA-domain proteins, which are conserved in many organisms including yeast, plants, nematodes and mammals (Wojtasz et al., 2009) . The HORMA-domain yeast homolog Hop1 is required for efficient DNA double-stain break (DSB) formation, synaptonemal complex (SC) formation and the prophase checkpoint (Schwacha and Kleckner, 1994; Bailis et al., 2000; Woltering et al., 2000; Carballo et al., 2008) . HORMAD1 also participates in the processes of SC formation, recombination and chromosome segregation (Shin et al., 2010) . Recently, it was shown that knockout of HORMAD1 disrupted DNA DSB formation in mice (Daniel et al., 2011) . The similar nuclear localization patterns of HORMADs in mammals (Wojtasz et al., 2009) , suggest that HORMAD2 is associated with the process of DNA DSB formation and meiotic progression. HORMAD1 has previously been identified as a CT gene named CT46 (Chen et al., 2005b) and this study confirms that HORMAD2 is also a CT gene. The HORMADs may represent a new CT gene family (HORMAD1/CT46.1 and HORMAD1/CT46.2). We demonstrated that nuclear expression of HORMAD2 is detected more frequently in early-stage lung adenocarcinoma, which indicates that HORMAD2 may be a candidate lung adenocarcinoma risk gene. Taken together with data from the literature, this study indicates that HORMADs/CT46 may play a role in DNA DSB or aneuploidy formation during tumorigenesis. It might contribute to molecular typing and immunotherapy of different lung cancers in the future. 
